KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

YUTOPAR 10 MG/ML INJECTION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

10 MG/ML

 

GENERIC NAME:

RITODRINE

 

MANUFACTURER:

DUPHAR B.V

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Labor, premature

 

SIDE EFFECTS:

Angina or cardiac disease, previously undiagnosed

diastolic blood pressure reduction, maternal

hyperglycemia, maternal

pulmonary edema

tachycardia or other cardiac arrhythmias, maternal and fetal

Agranulocytosis or leukopenia

hepatic function impairment or hepatitis

Erythema

headache

nausea

palpitations

trembling

vomiting

Psychological symptoms

skin rash

Shortness of breath

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Abruptio placentae

>> Hemorrhage, maternal

>> Placenta previa

>> Preeclampsia, mild to moderate

Allergy or sensitivity to ritodrine or sulfites

>> Diabetes mellitus

Hypertension

Migraine headaches

 

ADULT DOSE:

Tocolytic- Initial: Intravenous, 50 to 100 mcg (0.05 to 0.1 mg) per minute, increased every ten minutes as necessary in increments of 50 mcg (0.05 mg) to the effective dose that balances uterine response and unwanted effects (increased maternal heart rate and decreased blood pressure and increased fetal heart rate), or until the maternal heart rate reaches 130 beats per minute. Maintenance: Intravenous, 150 to 350 mcg (0.15 to 0.35 mg) per minute at the lowest dose that maintains a relaxed uterus; however, as soon as labor is irreversible or the maximum dose of 350 mcg (0.35 mg) per minute is reached, ritodrine should be discontinued. Note: Injection must be diluted before use unless premixed solution is used. Intravenous infusion should be continued for twelve to forty-eight hours after uterine contractions stop. Ritodrine should be administered in a separate intravenous line. Other medications of any type should not be administered via the same tubing.

 

MAXIMUM ADULT DOSE:

Intravenous, up to 350 mcg (0.35 mg) per minute.

 

PEDIATRIC DOSE:

 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT